Flamel Technologies leverages the competitive advantages of Medusa® and Micropump® via pharmaceutical and biotechnology partners.
In particular, the Company is seeking:
- Collaboration and Product/Research License opportunities for its Medusa and Micropump platforms and their specific applications i.e. respectively DeliVax™, LiquiTime™, and Trigger Lock™;
- License agreements for its in-house developed Medusa-based products and Micropump-based products;
- Co-development partnerships for the commercialization of Medusa-based Biobetters; and,
- Life cycle management (LCM) opportunities for its Micropump-based drugs.
